Verapamil
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Verapamil: From Hypertension and Arrhythmia to Obsolete Bundle Branch Block
One-Sentence Summary
Verapamil is a non-dihydropyridine calcium channel blocker whose pharmacological profile (AV-node conduction slowing) underlies its established use in hypertension and rate control of arrhythmias. TxGNN’s top-ranked prediction for this candidate is obsolete bundle branch block, but this direction is currently supported by 0 clinical trials and 0 publications, and the drug’s core mechanism runs counter to — rather than in support of — this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in India regulatory data (Verapamil is not marketed in India); per known pharmacology, used for hypertension and arrhythmia management |
| Predicted New Indication | Obsolete Bundle Branch Block |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data is not currently available for this drug. However, the evidence pack’s own pharmacological rationale describes Verapamil as a non-dihydropyridine calcium channel blocker with negative dromotropic activity — i.e., it slows conduction through the atrioventricular node — consistent with its recognized roles in hypertension and arrhythmia control.
For this specific top-ranked candidate, the mechanistic logic points in the wrong direction. Slowing AV and intraventricular conduction is generally viewed as a relative contraindication in the setting of bundle branch block, not a therapeutic rationale for it. In addition, “obsolete bundle branch block” appears to be an outdated or ambiguous disease-ontology term, which adds further uncertainty about whether this represents a clinically meaningful target.
Given these concerns, this prediction should be treated as a TxGNN score-driven pairing (Evidence Level L5) without independent clinical, preclinical, or mechanistic support, and is not currently a credible repurposing direction.
Note: Among the other TxGNN candidates generated for this drug, rank 2 (malignant renovascular hypertension) reached Evidence Level L4 with supporting literature and a “Research Question” recommendation — it may be a more productive direction for further evaluation than the top-ranked candidate above.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Verapamil currently holds no marketing authorizations in India (0 registrations; market status: Not Marketed). No product/authorization records are available to list.
Safety Considerations
Drug Interactions (328 total documented interactions in the evidence pack; selected examples below):
| Interacting Drug | Severity |
|---|---|
| Loperamide | Major |
| Hydrocortisone | Moderate |
| Metformin | Moderate |
| Bupropion | Moderate |
| Aprepitant | Moderate |
| Triamcinolone | Moderate |
| Acetylsalicylic acid | Moderate |
| Dexamethasone | Moderate |
| Betamethasone | Moderate |
| Clarithromycin | Moderate |
| Cimetidine | Moderate |
| Canagliflozin | Moderate |
| Morphine | Minor |
Formal TFDA/India-specific key warnings and contraindications are not yet available in this evidence pack (flagged as a blocking data gap — see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support (Evidence Level L5, decision stage S0), and its underlying mechanism (AV-node conduction slowing) is more consistent with a contraindication than a therapeutic rationale for bundle branch block. The disease label itself is also ontologically ambiguous.
To proceed, the following is needed:
- TFDA/India label warnings and contraindications (blocking gap, DG001) — required before any S1 safety screening
- Formal mechanism-of-action documentation for Verapamil (DG002)
- Clinical or clinical-ontology clarification of “obsolete bundle branch block” as a diagnostic category
- If this direction is pursued despite the above, cardiology input on conduction-system risk before any further evaluation
- Consider redirecting evaluation effort toward rank 2 (malignant renovascular hypertension), which has stronger evidence (L4) and an existing “Research Question” designation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.